News

Cerapedics Announces Publication of Two­ Year IDE Study Follow Up Data

Results published in Neurosurgery show peptide enhanced bone graft statistically superior to autograft in ACDF procedures at two years.

Oxford finance provides $20 Million senior debt facility to Cerapedics Inc.

Oxford Finance LLC (“Oxford”), an industryleading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $20 million senior secured term…

Cerapedics announces breakthrough technology agreement with Premier Inc.

Contract awarded for Breakthrough Technology: Bone Tissue Synthetic Implantable Products

Cerapedics receives Best New Technology Award for Spine Care at NASS Annual Meeting

Award recognizes i-FACTOR™ Peptide Enhanced Bone Graft based on the company’s synthetic small peptide (P-15) technology

Cerapedics announces closing of Series D financing

Funds to support expanded commercialization of i-FACTOR™ Peptide Enhanced Bone Graft

Cerapedics to participate in Canaccord Genuity's Musculoskeletal Conference

Cerapedics receives FDA approval for i-FACTOR Peptide Enhanced Bone Graft in Cervical Spine Surgery

Orthobiologics company positioned to begin commercial distribution in the U.S. following successful Premarket Approval application

Cerapedics announces FDA Advisory Committee Panel Is not required for i-FACTOR PMA Approval

Orthobiologics company has submitted response to remaining items from PMA review of i-FACTOR Peptide Enhanced Bone Graft

Cerapedics announces closing of loan and equity financing

Cerapedics, a privately-held orthobiologics company, today announced closing of a $4 million term loan from GE Capital, Healthcare Financial Services, bringing the total facility to $16.5 million. The company also a…

Study supports use of Cerapedics i-FACTOR Biologic Bone Graft as alternative to Autograft in common spine surgery for chronic back pain

Results published in International Journal of Spine Surgery